Literature DB >> 10904192

In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens.

J Dubois1, C St-Pierre.   

Abstract

The in vitro post-antibiotic effect (PAE) and batericidal activity of cefditoren was compared to that of cefixime, cefuroxime, loracarbef, cefaclor, amoxicillin, amoxicillin/clavulanate, clarithromycin, azithromycin, erythromycin, and ciprofloxacin against ATCC culture strains and clinical respiratory isolates. A PAE > 1 h was observed for cefditoren and generally for the macrolides against Streptococcus pneumoniae, beta-lactamase-negative Moraxella catarrhalis, and Streptococcus pyogenes, whereas the other beta-lactams showed mixed results. Cefditoren was the only beta-lactam showing significant bactericidal activity (>3 log reduction of viable cells) within 4 h against penicillin-resistant S. pneumoniae. Only cefditoren and ciprofloxacin showed significant bactericidal activity against beta-lactamase-negative (after 24 h) and beta-lactamase-positive strains of H. influenzae (after 12 h). Against beta-lactamase-positive strains of M. catarrhalis, cefditoren was the only agent to show significant bactericidal activity at 6 h (versus cefuroxime and ciprofloxacin at 12 h).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10904192     DOI: 10.1016/s0732-8893(00)00141-3

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

Review 1.  Cefuroxime axetil: an updated review of its use in the management of bacterial infections.

Authors:  L J Scott; D Ormrod; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Cefditoren pivoxil: a review of its use in the treatment of bacterial infections.

Authors:  Keri Wellington; Monique P Curran
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication.

Authors:  Francesco Blasi; Paolo Tarsia; Marco Mantero; Letizia C Morlacchi; Federico Piffer
Journal:  Ther Clin Risk Manag       Date:  2013-02-12       Impact factor: 2.423

Review 4.  Cefditoren pivoxil.

Authors:  Malcolm J M Darkes; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 11.431

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.